Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Mol Pharmacol ; 53(1): 6-13, 1998 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-9443927

RESUMEN

Receptor autoradiography with the Y2 receptor ligand 125I-peptide YY3-36 and in situ hybridization were applied to investigate changes in neuropeptide tyrosine-Y2 receptor expression after kainic acid-induced recurrent seizures in the rat hippocampus. In the strata oriens and radiatum of CA1 to CA3, which are densely innervated by Y2 receptor-bearing Schaffer collateral terminals, a transient 2-fold increase in Y2 receptor affinity was observed after 4-12 hr, with a later slow decline. No change was seen in Y2 mRNA expression in CA2/CA3 pyramidal cells, from which Schaffer collaterals originate. Conversely, in granule cells of the dentate gyrus, markedly elevated Y2 mRNA concentrations were observed (by 740% in the dorsal hippocampus) 24-48 hr after kainate injection. At the same time, a marked and lasting (up to 6 months) increase in the number of Y2 receptor sites (by 800%) was seen in the dentate hilus, which is innervated densely by mossy fibers. The early increase in Y2 receptor affinity in Schaffer collaterals was accompanied by a 60% decrease in the EC50 of peptide YY3-36 in inhibiting K(+)-stimulated glutamate release in hippocampal slices from kainic acid-treated rats. Our data indicate transient up-regulation of presynaptic Y2 receptors in Schaffer collaterals by a change in affinity and a permanent de novo synthesis of presynaptic Y2 receptors in granule cells/mossy fibers. These changes may cause augmented presynaptic inhibition of glutamate release from different hippocampal sites and, in conjunction with increased concentrations of neuropeptide tyrosine in mossy fibers, may represent an endogenous reactive anticonvulsant mechanism.


Asunto(s)
Epilepsia del Lóbulo Temporal/metabolismo , Receptores de Neuropéptido Y/biosíntesis , Animales , Autorradiografía , Conducta Animal/efectos de los fármacos , Unión Competitiva , Modelos Animales de Enfermedad , Agonistas de Aminoácidos Excitadores/farmacología , Ácido Glutámico/metabolismo , Hibridación in Situ , Radioisótopos de Yodo , Ácido Kaínico/farmacología , Cinética , Masculino , Fibras Musgosas del Hipocampo/ultraestructura , Fragmentos de Péptidos , Péptido YY/metabolismo , Péptido YY/farmacología , Células Piramidales/ultraestructura , ARN Mensajero/metabolismo , Ratas , Ratas Sprague-Dawley , Receptores de Neuropéptido Y/agonistas , Receptores de Neuropéptido Y/metabolismo , Regulación hacia Arriba/fisiología
2.
Int Arch Allergy Immunol ; 113(4): 424-31, 1997 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-9250588

RESUMEN

Encouraged by recent findings showing the usefulness of nonreplicating antigen delivery systems in the induction ofmucosal immune responses, we investigated microspheres as a means to deliver LW 50020, an immunomodulator consisting of lysates of seven common respiratory pathogens. BALB/c mice were orally immunized with LW 50020 encapsulated into poly-(D,L-lactide-co-glycolide) (PLG) and poly-(L-lactic acid) (PLA) microspheres prepared by either a solvent-evaporation or a solvent-extraction double-emulsion technique. Particle uptake into intestinal Peyer's patches, induction of antibodies in sera and secretion of immunoglobulins by isolated Peyer's patches, lungs and spleen lymphocytes were investigated. Our results revealed size and surface characteristic-dependent uptake of microspheres into Peyer's patches. Microsphere translocation into Peyer's patches was efficient for 0.8-microm microspheres, but poor for 2.0-microm and surface-modified microspheres. We showed an enhanced immune response in the lungs and sera following oral immunization with 0.8-microm PLG solvent-evaporation microspheres. The immunomodulation was statistically significant as compared to free LW 50020. In contrast, oral immunization with other preparations caused reduced or absent modulation of the immune response compared to 0.8-microm microspheres and free antigen. These findings indicate that microspheres displaying small particle sizes, rapid antigen release and high antigen content provide optimal tools to deliver orally applied antigens.


Asunto(s)
Vacunas Bacterianas/inmunología , Vacunación/métodos , Administración Oral , Animales , Anticuerpos Antibacterianos/análisis , Anticuerpos Antibacterianos/inmunología , Antígenos Bacterianos/inmunología , Vacunas Bacterianas/administración & dosificación , Técnica del Anticuerpo Fluorescente Indirecta , Inmunidad Mucosa , Inmunoglobulina G/inmunología , Inmunoglobulina G/metabolismo , Pulmón/inmunología , Pulmón/metabolismo , Linfocitos/inmunología , Linfocitos/metabolismo , Ratones , Ratones Endogámicos BALB C , Microscopía Electrónica de Rastreo , Microscopía Fluorescente , Microesferas , Ganglios Linfáticos Agregados/inmunología , Polímeros , Bazo/inmunología , Bazo/metabolismo
3.
Neurosci Lett ; 230(2): 129-32, 1997 Jul 18.
Artículo en Inglés | MEDLINE | ID: mdl-9259481

RESUMEN

Kainic acid-induced limbic seizures cause lasting increases in neuropeptide Y (NPY) expression in hippocampal granule cells/mossy fibers. The expression of NPY-Y1 receptors in these neurons were investigated, using in situ hybridization for Y1 mRNA and receptor autoradiography with the Y1-specific ligand [125I][Pro34]PYY. Six hours after kainic acid-induced seizures, Y1 receptor mRNA levels decreased by 80% in granule cells and concomitantly increased (by 75%) in CA2 pyramidal neurons. Subsequently, persistent decreases in Y1 mRNA were seen, both in the stratum granulosum and in CA2. Changes in mRNA concentrations were accompanied by a transient, although non-significant, increase in [125I][Pro34]PYY binding in the molecular layer of the dentate gyrus after 4-6 h which was succeeded by a lasting decrease in binding which indicates a persistent down-regulation of Y1 receptors in hippocampal areas in kainic acid-induced epilepsy.


Asunto(s)
Epilepsia/metabolismo , Hipocampo/metabolismo , Neuronas/metabolismo , Células Piramidales/metabolismo , Receptores de Neuropéptido Y/biosíntesis , Transcripción Genética , Animales , Autorradiografía , Giro Dentado/metabolismo , Epilepsia/inducido químicamente , Radioisótopos de Yodo , Ácido Kaínico , Masculino , Péptido YY , Péptidos/metabolismo , ARN Mensajero/biosíntesis , Ratas , Ratas Sprague-Dawley , Factores de Tiempo
4.
Vaccine ; 14(8): 792-8, 1996 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-8817827

RESUMEN

Cholera toxin (CT) and Escherichia coli heat-labile enterotoxin (LT) are the strongest mucosal immunogens identified to date and are also good adjuvants when given orally together in combination with unrelated antigens. We used these potent immunogens to monitor local and systemic immune responses following oral immunization of BALB/c mice, and compared their action on the following: (a) immunoglobulin production rates (IgG, IgM and IgA) in mucosal inductive (Peyer's patches-PPs), effector (intestinal lamina propria-LP, respiratory tract) and systemic (spleen) sites; (b) analysis of systemic antigen-specific antibodies (IgG subclasses, IgA and IgE); (c) time monitoring of fecal anti-CT and anti-LT antibodies, and (d) in vivo relevance of interleukin-6 (IL-6) to mucosal responses. Both mucosal immunogens elicited specific antibody responses (IgA, IgG) not only in the gastrointestinal tract (PP's and intestinal LP), but also in the respiratory tract and spleens of orally immunized mice. These mucosal responses were accompained by elevated secretion of IL-6 in all investigated tissues, indicating involvement of this cytokine in B-cell maturation processes. Furthermore, oral immunization with CT and LT induced elevated serum titers of IgG1 followed by IgG2a, IgG2b, IgG3 and IgA, while high antigen-specific IgA and IgG1 responses were found in fecal extracts. These findings illustrate the action of orally administered CT and LT, respectively, on several humoral and cellular immune responses not only at the gastrointestinal tract, the application site, but also in distant mucosal effector sites such as the respiratory tract. These data suggest the potential use of these mucosal adjuvants in oral immunization strategies to improve the local immune response in remote mucosal tissues, in accordance with the concept of a common mucosa-associated immune system.


Asunto(s)
Anticuerpos Antibacterianos/biosíntesis , Toxinas Bacterianas/administración & dosificación , Toxina del Cólera/administración & dosificación , Enterotoxinas/administración & dosificación , Proteínas de Escherichia coli , Inmunidad Celular/inmunología , Sistema Respiratorio/inmunología , Administración Oral , Animales , Escherichia coli/inmunología , Femenino , Inmunidad Mucosa , Ratones , Ratones Endogámicos BALB C
5.
J Immunol Methods ; 192(1-2): 25-35, 1996 Jun 10.
Artículo en Inglés | MEDLINE | ID: mdl-8699019

RESUMEN

Poly-(lactide-co-glycolide) microspheres with entrapped antigen have shown considerable promise as controlled release vaccines. To enhance the immunomodulatory effect of LW 50020, a bacterial lysate of seven common respiratory pathogens used perorally as an immunomodulator, we prepared poly-(D,L-lactide-co-glycolide) (PLG) and poly-(L-lactic acid) (PLA) microspheres with entrapped immunomodulator by solvent evaporation or solvent extraction double emulsion techniques. Physical properties, such as particle size, LW 50020 entrapment rate, antigen release patterns and morphological characteristics were investigated. All preparations displayed a high degree of antigen loading up to 95%, whereas size, surface morphology and antigen release patterns were significantly influenced by the method of preparation and the polymer components used. Solvent evaporation microspheres are porous particles from 0.8 micron to 2.0 microns in diameter, that show a rapid antigen release for PLG, and a moderate antigen release for PLA microspheres within 33 days. Solvent extraction microspheres have proven to be particles from 1.1 microns to 5.0 microns in diameter showing a smooth surface and a medium antigen release rate over 33 days. SDS-PAGE and immunoblotting of extracted antigen confirmed that the molecular weight and antigenicity of the immunomodulator remained unaltered by the entrapment procedure.


Asunto(s)
Adyuvantes Inmunológicos/química , Antígenos Bacterianos/química , Vacunas Bacterianas/química , Sistemas de Liberación de Medicamentos , Lactatos/química , Ácido Láctico , Ácido Poliglicólico , Polímeros/química , Sistema Respiratorio/inmunología , Animales , Antígenos Bacterianos/metabolismo , Preparaciones de Acción Retardada , Ratones , Ratones Endogámicos BALB C , Microesferas , Tamaño de la Partícula , Poliésteres , Copolímero de Ácido Poliláctico-Ácido Poliglicólico , Sistema Respiratorio/efectos de los fármacos , Propiedades de Superficie
6.
Wien Klin Wochenschr ; 108(14): 432-7, 1996.
Artículo en Alemán | MEDLINE | ID: mdl-8928514

RESUMEN

Due to its strategic position on mucosal surfaces secretory immunoglobulin A (sIgA) is one of the first protective factors of the specific immune system against invading pathogens. As a factor of acquired immunity, the synthesis of sIgA can be modulated by various immunization strategies. Our experiments aimed at the enhancement of the sIgA pool in the lungs by oral immunization. As reported previously, commercially available LW 50020, an immunomodulator consisting of lysates of seven common pneumotropic pathogens, is effective in inducing significant IgA antibody responses in the lungs following oral immunization [1]. In the present study we developed new strategies to enhance this effect by encapsulating LW 50020 into microspheres and liposomes. Microspheres and liposomes with entrapped immunomodulator each enhanced the effect of soluble LW 50020 by about 45% and 90%, respectively. In addition, microsphere based immunization induced a significantly increased immunoglobulin G (IgG) response in the lungs. In further experiments we demonstrated that a similar effect could be achieved by administration of a high molecular weight conjugate of lipopolysaccharide from Klebsiella pneumoniae (LPS) and lipoteichoic acid from Streptococcus pyogenes (LTA). This conjugate enhanced the synthesis of IgA in the lungs by 45% and, furthermore, induced a significantly enhanced IgG response in the lungs, without any obvious toxic or pyrogenic side effects. This new conjugate possibly offers an opportunity to replace the complex immunomodulator LW 50020 by a less complex vaccine.


Asunto(s)
Adyuvantes Inmunológicos , Vacunas Bacterianas/inmunología , Inmunoglobulina A Secretora/biosíntesis , Inmunoterapia Activa , Pulmón/inmunología , Adyuvantes Inmunológicos/administración & dosificación , Administración Oral , Animales , Vacunas Bacterianas/administración & dosificación , Portadores de Fármacos , Femenino , Inmunoglobulina G/biosíntesis , Inmunoglobulina M/biosíntesis , Liposomas , Ratones , Ratones Endogámicos BALB C , Microesferas
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...